Crohn's News Blog

Weblog – Informação sobre DII

Humira most favored among biologics for Crohn’s disease and ulcerative colitis

leave a comment »

Health | Crohn’s disease | Humira

Abbott/Eisai’s Humira most favored among biologics for Crohn’s disease and ulcerative colitis, says DR report

US gastroenterologists survey by USA-based advisory firm Decision Resources estimate that (assuming no new data on adverse events emerge) they will treat fewer Crohn’s disease patients with Centocor Ortho Biotech/Merck/Mitsubishi Tanabe’s Remicade (infliximab) by the end of 2010, while the percentage of biologics-treated patients receiving Abbott/Eisai’s Humira (adalimumab) will increase to 36%. Surveyed gastroenterologists also indicate that the percentage of patients treated with a biologic who receive UCB/Otsuka’s Cimzia (certolizumab pegol) will rise from 9% to 12% within the next year.

DR’s new Physician & Payer Forum report, titled The Expanding Biologics Landscape in CD and UC: Clinician and Payer Perspective on the Role of Premium-Priced Biologics in CD and UC Treatment also finds that, on average, surveyed gastroenterologists report prescribing Remicade to 31% of their ulcerative colitis patients.

Deixe uma Resposta

Preencha os seus detalhes abaixo ou clique num ícone para iniciar sessão:

Logótipo da WordPress.com

Está a comentar usando a sua conta WordPress.com Terminar Sessão / Alterar )

Imagem do Twitter

Está a comentar usando a sua conta Twitter Terminar Sessão / Alterar )

Facebook photo

Está a comentar usando a sua conta Facebook Terminar Sessão / Alterar )

Google+ photo

Está a comentar usando a sua conta Google+ Terminar Sessão / Alterar )

Connecting to %s

%d bloggers like this: